What Is Sapropterin?
Sapropterin, sold as Kuvan, is a synthetic form of tetrahydrobiopterin (BH4), a naturally occurring cofactor essential for several enzymatic reactions.[1] It does not control or produce cofactors; instead, it acts as a pharmaceutical replacement for BH4 to restore its levels in patients with deficiencies.
How Does Sapropterin Function as a BH4 Cofactor?
BH4 serves as a cofactor for phenylalanine hydroxylase (PAH), tyrosine hydroxylase, and tryptophan hydroxylase, enabling the breakdown of phenylalanine (Phe) into tyrosine and the synthesis of neurotransmitters like dopamine and serotonin.[2] In PKU patients with PAH mutations, residual enzyme activity exists but requires high BH4 levels. Sapropterin binds directly to PAH, stabilizing it, enhancing its activity, and lowering blood Phe levels by up to 30-50% in responders.[3]
Why Is It Used in PKU Treatment?
Sapropterin treats tetrahydrobiopterin deficiency and PAH-responsive PKU, allowing better Phe control without strict dietary restrictions.[4] About 20-30% of PKU patients respond, identified via loading tests where Phe drops significantly after dosing.
What Happens Without Enough BH4?
Low BH4 leads to hyperphenylalaninemia, causing intellectual disability, seizures, and neurotransmitter shortages in untreated PKU.[5] Sapropterin bypasses this by providing exogenous BH4, but it requires daily dosing (5-20 mg/kg) and monitoring, as endogenous BH4 production remains impaired.
Differences from Natural BH4 Production
The body produces BH4 via the GTP cyclohydrolase pathway in liver and brain cells, regulated by demand.[6] Sapropterin supplements this but does not stimulate production; it is oxidized to inactive forms (BH2) and recycled via dihydrobiopterin reductase, mimicking natural cycling.
[1]: DrugPatentWatch.com - Sapropterin Patents
[2]: FDA Label - Kuvan
[3]: Blau N, et al. Mol Genet Metab. 2010.
[4]: Vockley J, et al. Mol Genet Metab. 2014.
[5]: van Spronsen FJ, et al. Orphanet J Rare Dis. 2017.
[6]: Thöny B, et al. Biochem J. 2000.